Skip to main content
SpringerLink
Log in

Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Disturbances in the fibrinolytic system have been associated with cardiovascular disease and its risk factors. In the present study the effects of an alpha1-adrenoceptor inhibitor (doxazosin) and a selective beta-adrenoceptor blocker (atenolol) on the fibrinolytic system have been evaluated.

Eighty four subjects with previously untreated mild to moderate hypertension and elevated serum cholesterol were randomized to receive atenolol or doxazosin in a double-blind study over 6 months. Tissue plasminogen activator(tPA) and plasminogen activator inhibitor (PAI-1) were measured in citrated plasma samples before and after venous occlusion before and at the end of the study period.

tPA activity after venous occlusion and tPA capacity were significantly increased after doxazosin as compared to pretreatment values. The fibrinolytic variables did not change in the atenolol group.

Thus, doxazosin but not atenolol, improved the activity of the fibrinolytic system in patients with hypertension and an elevated serum cholesterol level. This effect of doxazosin warrants consideration when selecting a first-line antihypertensive drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effect of treatment on morbidity in hypertension. Results in patients with diastolic pressure averaging 115 through 129 mm Hg. JAMA 202: 116–122

    Google Scholar 

  2. Veterans Adminstration Cooperative Study Group on Antihypertensive Agents (1970) Effect of treatment on morbidity in hypertension. II. Results in patients with diastolic pressure averaging 90 through 114 mm Hg. JAMA 213: 1143–1152

    Google Scholar 

  3. Hypertension Detection and Follow-up Program Cooperative Group (1979) Five-year findings of the hypertension detection and follow-up program. JAMA 242: 2562–2571

    Google Scholar 

  4. Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248: 1465–1477

    Google Scholar 

  5. Samuelsson O (1985) Hypertension in middle-aged men: Management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand [Suppl] 702: 1–79

    Google Scholar 

  6. Isles GC, Walker LM, Beevers GD, et al. (1986) Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 4: 141–156

    Google Scholar 

  7. Bulpitt CJ, Beevers G, Butler A, et al. (1986) The survival of treated hypertensive patients and their causes of death: A report from the DHSS Hypertensive Care Computing Project (DHCCP). J Hypertens 4: 93–100

    Google Scholar 

  8. Helgeland A (1980) Treatment of mild hypertension: a five-year controlled drug trial. The Oslo Study. AJR 69: 725–732

    Google Scholar 

  9. Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. Br Med J 291: 97–104

    Google Scholar 

  10. Leren P (1985) The hypertension-CHD dilemma. Acta Med Scand 217: 145–7

    Google Scholar 

  11. Stamler J, Stamler R, Liu K (1985) High blood pressure: role in coronary heart disease and implications for prevention and control. In: Connor W, Bristow (eds) Coronary heart disease. Lippincott, Philadelphia, p 85

    Google Scholar 

  12. Carlsson LA, Åberg H (1985) Serum triglycerides — an independent risk factor for myocardial infarction but not for angina pectoris. N Engl J Med 312: 1127

    Google Scholar 

  13. Carlsson LA, Böttiger LE, Åfeldt PE (1979) Risk factors for myocardial infarction in the Stockholm prospective study — A 14 year follow-up focusing on the role of plasma triglyceride and cholesterol. Acta Med Scand 206: 351

    Google Scholar 

  14. Hamsten A, Wiman B, De Faire U, Blombäck M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557–1563

    Google Scholar 

  15. Hamsten A, Walldius G, Blombäck M, de Faire U, Dahlén G, Landou C, Wiman B (1987) Plasminogen activator inhibitor in plasma: riskfactor for recurrent myocardial infarction. Lancet II: 3–8

    Google Scholar 

  16. Nilsson TK, Johnson O (1987) The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 48: 621–630

    Google Scholar 

  17. Olofsson B-O, Dahlén G, Nilsson TK (1989) Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 10: 77–82

    Google Scholar 

  18. Nilsson TK, Lithner F (1988) Glycaemic control, smoking habits and diabetes duration affect the extrinsic fibrinolytic system in type I diabetic patients but microangiopathy does not. Acta Med Scand 224: 123–129

    Google Scholar 

  19. Sundell B, Nilsson TK, Nygren C, Hallmans G, Hellsten G, Dahlén GH (1989) Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in an North Swedish population. Atherosclerosis 80: 9–16

    Google Scholar 

  20. Simpson HCR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L (1983) Hypertriglyceridaemia and hypercoagulability. Lancet I: 786–790

    Google Scholar 

  21. Andersen P, Nilsen DWT, Beckman SL, Holme I, Hjermann I (1988) Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals. Acta Med Scand 223: 499–506

    Google Scholar 

  22. Meade TW, Brozovic M, Chakrabarti R, et al. (1986) Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart study. Lancet I: 533–537

    Google Scholar 

  23. Jansson JH (1990) Studies on haemostatis in deep vein thrombosis, ischaemic heart disease and hypertension. Umeå University Medical Dissertations New Series No 295 Paper V

  24. Huhtasaari F, Asplund K, Wester PO (1988) Cardiovascular risk factors in the northern Sweden MONICA study. Acta Med Scand 224: 99–108

    Google Scholar 

  25. Nyström L, Rosén M, Wall S (1986) Why are diabetes, stomach cancer and circulatory diseases more common in Northern Sweden? Scand J Prim Hlth Care 4: 5–12

    Google Scholar 

  26. Krarup NB (1956) Fetma. Vår Hälsa 9: 3–14

    Google Scholar 

  27. Grimaudo V, Hauert J, Bachman F, Kruithof EKO (1988) Diurnal variation of the fibrinolytic system. Thromb Haemostas 59: 495–499

    Google Scholar 

  28. Bergsdorf N, Nilsson T, Wallén P (1983) An enzyme-linked immunosorbent assay for tissue plaminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 50: 740–744

    Google Scholar 

  29. Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G (1986) Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 32: 2160–2165

    Google Scholar 

  30. Wiman B, Mellbring G, Rånby M (1983) Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 127: 279–288

    Google Scholar 

  31. Chmielewska J, Rånby M, Wiman B (1983) Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31: 427–436

    Google Scholar 

  32. Paramo JA, Colucci M, Collen D, van de Werf P (1985) Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 291: 573–574

    Google Scholar 

  33. Aznar J, Estellés A, Tormo G et al. (1988) Plasminogen activator inhibitor and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59: 535–541

    Google Scholar 

  34. Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI (1988) Impaired fibrinolysis in coronary artery disease. Am Heart J 115: 776–780

    Google Scholar 

  35. Mehrotra TN, Mehrotra R (1987) Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in cases of essential hypertension. J Postgraduate Med 33: 178–181

    Google Scholar 

  36. Reference deleted

  37. Kartsev AN (1986) Fibrinolysis and platelet reactivity in patients with essential hypertension and coronary atherosclerosis. Klinicheskaia meditsina 64: 103–107 (in Russian)

    Google Scholar 

  38. Khamidov NK, Khamdamova MB (1987) Fibrinolytic blood system in ischemic heart disease concurrent with arterial hypertension in middle and old age. Klinicheskaia meditsina 65: 74–76 (in Russian)

    Google Scholar 

  39. Jansson JH (1990) Studies on haemostasis in deep vein thrombosis, ischaemic heart disease and hypertension. Umeå University Medical Dissertations New Series No. 295 Paper V

  40. Elkeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade TW (1980) Effect of treatment of hyperlipidemia on haemostatic variables. Br Med J 281: 973–974

    Google Scholar 

  41. Sacks FM, Dzau VJ (1986) Adrenergic effects on plasma lipoprotein metabolism. Am J Med 80 [Suppl 2A]: 71

    Google Scholar 

  42. Frick H, Cox D, Himanen P et al. (1987) Serum lipid changes in a one-year multicenter, double-blind comparison of doxazosin and Atenolol for mild to moderate essential hypertension. Am J Cardiol 59: 616–676

    Google Scholar 

  43. Trost B, Weidmann P, Riesen W, Claessens J, Streulens Y, Nelemans F (1987) Comparing effects of doxazosin and hydrochlortiazidd on serum lipids and blood pressure in essential hypertension. Am J Cardiol 59: 996–1046

    Google Scholar 

  44. Hjortdal P, von Krogh H, Daae L, Holme I, Hjerman I (1987) A 24-week multicenter double-blind study of doxazosin and hydrochlorthiazide in patients with mild to moderate essential hypertension. Acta Med Scand 221: 427–434

    Google Scholar 

  45. Holemans R (1963) Enchancing the fibrinolytic activity of the blood by vasoactive drugs. Med Exp 9: 5–12

    Google Scholar 

  46. Gader AMA, Clarkson AR, Cash JD (1973) The plasminogen activator and coagulation factor VIII response to adrenaline, noradrenaline, isoprenaline and salbutamol in man. Thromb Res 2: 9–16

    Google Scholar 

  47. Kral JG, Åblad B, Johnsson G, Korsan-Bengtsson K (1971) Effects of adrenaline and alprenolol on blood coagulation and fibrinolysis in man. Eur J Clin Pharmacol 3: 144–147

    Google Scholar 

  48. Probst A, Lill H, Strain KM (1988) Beta-adrenergic receptor mediated release of tissue plasminogen activator in anaesthetized dogs. Thromb Res 50: 9–17

    Google Scholar 

  49. Winther K (1987) The effect of beta-blockade on platelet function and fibrinolytic activity. J Cardiovasc Pharmacol 10 [Suppl 2]: S 94–98

    Google Scholar 

  50. Johannessen KA, Nordrehaug JE, von der Lippe G (1987) Increased occurrence of left ventricular thrombi during early treatment with timolol in patients with myocardial infarction. Circulation 75: 151–155

    Google Scholar 

  51. Alexander GGT, Robinson JG, Doyle DJ et al. (1989 Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 320: 352–357

    Google Scholar 

  52. Norwegian Study group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801

    Google Scholar 

  53. Beta-Blocker Heart Attack Trial Research Group (1982) A randomized trial of propanolol in acute myocardial infarction. I. Mortality results. JAMA 247: 1707

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Skellefteå Hospital, Skellefteå, Sweden

    J. -H. Jansson & K. Boman

  2. Community Health Organisation, Skellefteå, Sweden

    B. Johansson

  3. Department of Clinical Chemistry, Umeå Hospital, Sweden

    T. K. Nilsson

Authors
  1. J. -H. Jansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Boman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. K. Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jansson, J.H., Johansson, B., Boman, K. et al. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol 40, 321–326 (1991). https://doi.org/10.1007/BF00265838

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00265838

Key words

Search

Navigation